BioLineRx (BLRX) is about to face one of its defining moments in 1Q 2013, when results of an interim analysis from the phase 2/3 CLARITY study of BL-1020 are expected to be released. BL-1020, BioLine's leading drug candidate, is an orally available GABA-enhanced antipsychotic for the treatment of both the positive and cognitive effects of schizophrenia. The cognitive impairment associated with schizophrenia (OTC:CIAS), which is less recognized than the positive effects of the condition (reasonably treated by current antipsychotics), is exhibited as deterioration of long-term memory, concentration and ability to perform executive functions. CIAS affects the vast majority of schizophrenia patients and severely damages their overall functional and quality of life outcomes.
We think that the...
Only subscribers can access this article, which is part of the PRO research library covering 3,573 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: